Effects of Aripiprazole Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder (A Double Blind Clinical Trial)

Sayyah, Mehdi; Sayyah, Mohammad; Boostani, Hatam; Ghaffari, Seyyed Mohammad; Hoseini, Abedin

doi:10.1002/da.21996

Cited by 87 publications

(62 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Aripiprazolle ilgili sonuçlar net olmamakla beraber dirençli OKB hastalarında yapılan çift kör bir çalışmada aripiprazolün faydalı olduğu gösterilmiştir. 7 Onikofajinin eşlik ettiği yaygın anksiyete bozukluğu hastasında essitaloprama aripiprazol eklenmesi ile onikofaji semptomlarının düzelmesi ve bu faydanın takiplerde de devam etmesi önerimizi desteklemektedir. Sonuç olarak, onikofajisi olan yaygın anksiyete bozukluğu hastalarında tedaviye aripiprazol eklenmesi faydalı olabilir.…”

Section: Discussionunclassified

See 1 more Smart Citation

Add-on treatment of aripiprazole in an adult onychophagia patient

Kaya

Bulut²,

Bez³

2012

J Clin Exp Invest

View full text Add to dashboard Cite

Nail biting (onychophagia) is a common disorder which has not been investigated yet. There are different opinions about to classify onychophagia, but according to DSM-IV-TR it is classified as impulse control disorder not otherwise specified. The knowledge about treatment of onychophagia is limited. There are a few studies about treatment of onychophagia with psychotherapy and a study with pharmacotherapy. Some studies suggest that an atypical antipsychotic aripiprazole may have beneficial effects in the treatment of impulse control disorders. In this study we report a case of onychophagia which has successfully treated with aripiprazole add-on to escitalopram treatment that has never reported before. J Clin Exp Invest 2012; 3(4): 545-547

show abstract

Section: Discussionunclassified

“…3,4 Hem dürtü kontrol bozukluklarında hem de OKB'de aripiprazolün faydalı olabileceği bazı çalışmalarda gösterilmiştir. 6,7 Bu yazıda literatürde daha önce bildirilmemiş olan essitalopram tedavisine aripiprazol eklenmesiyle başarılı bir şekilde tedavi edilen onikofaji vakasını sunmayı amaçladık. …”

unclassified

Add-on treatment of aripiprazole in an adult onychophagia patient

Kaya

Bulut²,

Bez³

2012

J Clin Exp Invest

View full text Add to dashboard Cite

show abstract

“…Indeed, neurons in the midbrain raphe nuclei project to the ventromedial the treatment of resistant OCD [5,8,[30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46]. The designs of these studies are heteregenous as regard the duration of the antipsychotic treatment (8 to 12 weeks), the severity of the patients included (Y-BOCS scores), the response criteria (decrease of 25% or 35% of the Y-BOCS) and the presence of comorbidities (including tics and schizotypal personality disorder, not systematically evaluated).…”

Section: Dopaminergic Modelmentioning

confidence: 99%

Neurobiology and Effectiveness of Antipsychotic Drugs in Resistant Obsessive-Compulsive Disorder: A Systematic Review

Ducasse¹,

Fond²,

Mondor³

2013

J Depress Anxiety

View full text Add to dashboard Cite

Aims of the StudyTo synthesize in a comprehensive review, the mechanistic hypotheses of antipsychotic potential activity in OCD and to summarize clinical trials on the effectiveness of antipsychotic drugs in OCD, in monotherapy or in combination with SSRIs.A systematic review of the literature was conducted using PRISMA criteria. The paradigm search was "obsessive compulsive disorder and antipsychotic agents". Medline, Cochrane and Web of science databases were explored without date or language restriction. Case reports, open label studies and randomized double-blind controlled trials were included in the qualitative review.Unlike the classical serotonergic hypothesis, OCD may result from striatal dopaminergic hyperactivity, modulated in some patients by an underlying serotonergic hypo activity. In the treatment of resistant OCD, most studies report the effectiveness of first-generation antipsychotic (haloperidol, amisulpride) and some second-generation antipsychotics (risperidone, olanzapine, aripiprazole, quetiapine) in combination with an SSRI. Moreover, in case reports, recrudescence or onset of OCD symptoms in patients with schizophrenia have been described in a switch from first generation antipsychotic medication to olanzapine, risperidone, aripiprazole or clozapine, but not within a switch to amisulpride or quetiapine.These preliminary results on the use of antipsychotic medication in OCD deserve further investigation for potential guideline updates.Obsessive-Compulsive Disorder (OCD) is "the presence of recurrent ego-dystonic and intrusive thoughts or images (obsessions), with ritualized behaviors (compulsions) performed in order to neutralize obsessive thoughts" [1]. The lifetime prevalence of OCD in France in 2006 was 2 to 3%, its prevalence over a period of 6 months was 1 to 2% and the sex ratio is 1 [2]. In the USA, in 2005, OCD was recognized as a fairly common psychological disorder with reported lifetime prevalence between 1.6 and 3.3%, and 1 year prevalence between 1.0 and 2.1% "Resistant OCD" may be defined as OCD whose symptoms persist after treatment by SSRIs in high doses for at least 8 weeks [2]. The SSRI response-rate is only 40% to 60% of patients [4]. Whereas resistant OCD is typically explained by serotonin mechanisms, another neurobiological mechanisms are involved [5]. For example, in some patients, dopaminergic hyperactivity modulated by an underlying serotonergic hypo activity has been suggested [6].Antipsychotics have been suggested as second-line treatment in resistant OCD with a controversial effectiveness [7]. At first sight, risperidone's effectiveness in resistant OCD [8] seems paradoxical: if OCD is conceived as a serotonin deficiency, the coprescription of a 5-HT antagonist with a SSRI should worsen OCD symptomatology. Moreover, low doses of risperidone (<3 mg/d) have found to be the best effective where the anti-5-HT2A activity is optimal with a very low anti-D2 activity [9,10]. Finally, some second-generation antipsychotics have been involved in de novo OCD genesis in psyc...

show abstract

“…Besides, mood stabilizers, gamma-amino-butyric acid (GABA) analogues and GABA reuptake inhibitors, benzodiazepines and glutamatergic agents are other treatment options (9). Many studies and case reports revealed efficacy of augmentation with antipsychotics, such as aripiprazole, an antipsychotic showing partial agonism at serotonin 5-hydroxytryptamine (5-HT)-1A receptors, and antagonism at 5-HT2A receptors (13), in patients who had inadequate OCD treatment response (10)(11)(12).…”

Section: Introductionmentioning

confidence: 99%

Aripiprazole augmentation of clomipramine therapy in treatment-resistant obsessive-compulsive disorder: case series

İzci¹,

Yalçın²,

Calli³

et al. 2016

Dusunen Adam

View full text Add to dashboard Cite

show abstract

Effects of Aripiprazole Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder (A Double Blind Clinical Trial)

Abstract: Results of the present study indicate that aripiprazole could be an effective augmentation medicine in treatment resistant OCD.

Cited by 87 publications

References 22 publications

Add-on treatment of aripiprazole in an adult onychophagia patient

Add-on treatment of aripiprazole in an adult onychophagia patient

Neurobiology and Effectiveness of Antipsychotic Drugs in Resistant Obsessive-Compulsive Disorder: A Systematic Review

Aripiprazole augmentation of clomipramine therapy in treatment-resistant obsessive-compulsive disorder: case series

Contact Info

Product

Resources

About